In this article, you can read the instructions for using the drug Etamsilat... The reviews of website visitors - consumers of this medicine, as well as opinions of doctors of specialists on the use of Etamzilat in their practice are presented. A big request is to actively add your reviews about the drug: whether the medicine helped or did not help get rid of the disease, what complications and side effects were observed that may not have been declared by the manufacturer in the annotation. Etamsilat analogs in the presence of available structural analogs. Use for the treatment of bleeding during menstruation, in surgery and dentistry in adults, children, as well as during pregnancy and lactation.
Etamsilat - antihemorrhagic agent. It normalizes the permeability of the vascular wall, improves microcirculation. The action is, apparently, associated with an activating effect on the formation of thromboplastin. Does not affect prothrombin time, does not have hypercoagulable properties and does not contribute to the formation of blood clots.
The onset of action is 5-15 minutes after intravenous injection, the maximum effect is 1-2 hours after administration. The duration of action is 4-6 hours.
Composition
Etamsylate + excipients.
Pharmacokinetics
About 72% of the administered dose is excreted unchanged in the urine during the first 24 hours. Penetrates through the placental barrier, excreted in breast milk.
Indications
- prevention and treatment of capillary bleeding in diabetic angiopathies, during surgical interventions in otolaryngological practice, in ophthalmology, dentistry, urology, surgery and gynecology;
- emergency cases with intestinal and pulmonary bleeding, with hemorrhagic diathesis.
Release forms
Tablets 250 mg.
Solution for intravenous and intramuscular administration (injections in ampoules for injection).
Instructions for use and dosage
When taken orally - 250-500 mg 3-4 times a day, intramuscularly or intravenously - 125-250 mg 3-4 times a day. If necessary, a single dose for oral administration can be increased to 750 mg, for parenteral administration up to 375 mg.
Children - 10-15 mg / kg per day, frequency of use - 3 times a day in equal doses.
For external use, a sterile swab soaked in ethamsylate (in the form of a solution for injection) is applied to the wound.
Side effect
- heartburn;
- a feeling of heaviness in the epigastric region;
- headache;
- dizziness;
- hyperemia of the face;
- decrease in systolic blood pressure;
- paresthesia of the lower extremities.
Contraindications
- thrombosis;
- thromboembolism;
- hypersensitivity to etamsylate.
Application during pregnancy and lactation
During pregnancy, it is possible if the expected effect of therapy outweighs the potential risk to the fetus (the safety of using etamsylate during pregnancy has not been established). During treatment, breastfeeding should be discontinued.
Application in children
Application is possible according to the dosage regimen.
special instructions
Etamsylate should not be used as the only remedy if the patient has hemorrhages caused by anticoagulants.
Drug interactions
Pharmaceutical incompatible with other drugs. Should not be mixed in the same syringe with other drugs.
A combination with aminocaproic acid, sodium menadione, bisulfite is acceptable.
Analogues of the drug Etamsilat
Structural analogues for the active substance:
- Dicinon;
- Etamsilat Ferein;
- Etamsilat Eskom;
- Etamsilata solution for injection 12.5%.
In the absence of analogues of the drug for the active substance, you can follow the links below to the diseases for which the corresponding drug helps, and see the available analogues for the therapeutic effect.
Angioprotector and microcirculation corrector. Application: angiopathy, bleeding, hemorrhagic diathesis. Price from 120 rubles.
Analogs: Ditsinon, Vikasol, Octanate.
What kind of drug
Etamsylate - injections for intravenous, intramuscular injection. The drug belongs to the group of hemostatics, angioprotectors.
Active ingredient and composition
1 ml of solution contains 125 mg of the main ingredient - etamsylate.
Additional components in the composition of Etamsilat injections:
- sodium sulfite and disulfide;
- edetate disodium;
- water for injections.
Pharmacological properties
Etamsylate is a hemostatic agent, an angioprotector.
Properties:
- restores the process of blood coagulation;
- increases the elasticity, stability of the capillary walls;
- normalizes blood microcirculation in various vessels.
Even with prolonged therapy, blood clots do not form, since the drug does not affect the prothrombin index.
Pharmacodynamics and pharmacokinetics
The drug activates the synthesis of mucopolysaccharides and thromboplastin, which leads to the suppression of hemostatic activity.
After intravenous administration, the results of active action are noticeable after 10 minutes and are observed for 6-8 hours.
Approximately 72% of the active substance is excreted unchanged in the urine during the day. The half-life is 2 hours.
Indications for use
The drug is used to treat and prevent capillary bleeding. Etamsylate in ampoules is used in dentistry, ophthalmology, urology and gynecology, surgery.
Etamsilat - indications for use:
- diabetic angiopathy;
- uterine and other internal bleeding;
- surgical interventions - tonsillectomy, prostatectomy, keratoplasty, cataract removal, dental surgery;
- injuries that are accompanied by bleeding;
- hemorrhagic diathesis.
A medicine is sometimes prescribed for polymenorrhea to prevent the development of anemia.
Contraindications
Etamsilat is contraindicated for use with hypersensitivity to the components of drugs.
Method of administration and dosage
The daily dose is 0.125-0.25 g, administered at intervals of 6-8 hours. The maximum permissible single dose is 0.375 g.
The solution can be impregnated with a sterile dressing, used for wounds as a compress.
In childhood, during pregnancy and hepatitis B
The drug is not prescribed in the first trimester of pregnancy. At a later date, the drug is used with extreme caution under constant medical supervision.
In pediatric practice, it is possible to use the drug, according to the appropriate indications and the exact calculation of the required dose.
Side effects
Sometimes negative reactions appear during therapeutic protocols:
- heartburn;
- heaviness in the epigastric region;
- headache, attacks of dizziness;
- redness of the skin of the face;
- decrease in systolic blood pressure;
- paresthesia of the lower extremities.
special instructions
The drug cannot be used as the only drug for hemorrhage caused by intake.
Overdose
There are no data on the cases of the consequences of exceeding the dose in the instructions for use for Etamzilat.
Drug interactions
Do not mix Etamsilate in the same syringe with any other medications.
Analogs
Etamzilat's analogs:
- by composition - Ditsynon;
- on therapeutic action - Tincture of water pepper, Emaplag, Eltrombopach, Vikasol, Octanate.
Each drug has its own list of indications and contraindications. Replacement of the drug can only be prescribed by the attending physician.
In this material you will find instructions for the use of the solution for injection (injections) of the drug Etamsilat and cases of its use.
Etamsilate injection
One 2 ml ampoule of the drug contains 250 ml of active ingredient. Available in packs of 5 or 10 ampoules.
Pharmacological properties
This drug is a hemostatic (hemostatic) drug. The hemostatic effect is due to an increase in the interaction between platelets and the endothelium. The drug stabilizes the capillary walls, reduces their permeability. Due to the ability to inhibit the synthesis of prostalangins, the drug reduces bleeding time, reduces the volume of lost blood. In addition, the agent promotes the fastest formation of a primary thrombus, practically without affecting the prothrombin time and the level of fibrinogen.
With intravenous administration, it occurs in 10-15 minutes, with intramuscular administration of the drug, the effect occurs after a longer time - after 30-60 minutes.
Indications for the use of solution for injection
The drug is indicated for use in various medical practices - obstetrics, gynecology, otorhinolaryngology, dentistry, ophthalmology, in plastic surgery:
- with capillary bleeding of various origins, especially in cases of damaged endothelium;
- as a prophylaxis and to stop bleeding during surgery on vascularized tissue and after surgery;
- as prevention and treatment of capillary bleeding of various origins and localization;
- with hematuria, primary menorrhagia, metrorrhagia, menorrhagia in patients with intrauterine contraceptives;
- with bleeding gums.
Special instructions for the use of Etamsilat in solution
Dosage
Etamsylate in ampoules for intravenous and intramuscular administration is applied at 125-250 mg up to 4 times a day.
The dose for administration of the drug, bypassing the digestive tract, is a maximum of 375 mg.
As a solution for external use, soak a cotton swab with Etamsilat solution and apply to the wound surface.
Contraindications to the use of the drug Etamsilat
- Excessive sensitivity to the active substance.
- Tendency to thrombosis.
- The use of Etamsilat as monotherapy with a tendency to bleeding and hemorrhage.
Etamsilat is used as a hemostatic agent, injections have an angioprotective effect. The medication is necessary in the complex therapy of massive bleeding in gynecology. The drug helps to ensure stable hemostasis.
The medicine is produced by Eskom. The medication is represented by a solution for injection. It consists of: active ingredient - Etamsylate, as well as additional ingredients: sodium disulfide, disodium edetate, water for injections.
The hemostatic agent is placed in ampoules, produced in cardboard boxes containing 10 pcs. drug.
1 ampoule contains 2 ml of solution, 125 g of active ingredient in 1 ml of liquid. 10 pcs of the preparation and the scarifier can sometimes be placed in a honeycomb package. The ampoules have a break ring or a special notch.
Pharmacology and pharmacokinetics
The drug stops the blood. The drug affects the formation of non-nuclear shaped elements, facilitates their appearance from the cells of the spinal cord. Stopping bleeding occurs by reducing the formation of prostacyclin with a simultaneous increase in the amount of thromboplastin.
The thrombus forms quickly, but this process is not associated with the amount of fibrinogen and the duration of prothrombin time.
Secondary administration of the drug accelerates the formation of a blood clot. The drug increases the stability of small vessels, regulates their strength, affects vascular leaks in various diseases.
A hemostatic agent regulates the process of microcirculation in tissues, has a low coagulation activity, and dilates blood vessels. The therapeutic effect develops within a quarter of an hour after its intravenous injection, lasts about a day. After an i / m injection, the effect is short-lived.
The drug is rapidly absorbed after i / m administration, is evenly distributed in organs and tissues, and is removed through the kidneys and bile ducts.
The bioavailability of the drug is 120 minutes. The drug is removed from organs and tissues in 4 hours.
Indications and contraindications
Etamzilat solution is effective in the treatment of the following diseases: capillary damage, violation of the integrity of the vessels of the kidneys and liver, intracranial hematoma, predisposition to hemorrhage, rhinopathy in diabetes mellitus, with bleeding in gynecology.
The drug should not be used in the following pathological conditions: individual drug intolerance, thrombosis, embolism, pregnancy, breastfeeding. While taking medications that prevent blood clotting, hemorrhages may appear.
In this case Etamsilat is contraindicated in the patient. The hemostatic agent is not used in patients suffering from lymphatic leukemia, osteosarcoma, hemoblastosis.
Etamsilate in ampoules instructions for use
Etamzilate injections belong to antihemorrhagic drugs, the instructions for use regulate the procedure for prescribing and using the drug. After reading the description of the drug, the patient learns the procedure for its use, dose, indications and contraindications for admission.
The medicine is partially used in veterinary medicine to prevent blood loss.
Do not use a hemostatic agent in women suffering from a fibrous tumor in the uterus.
Another drawback of the drug is the formation of severe leukopenia in patients with hemoblastosis. In this case, the cellular composition of the blood contains less than 4.0 liters of leukocytes. The medicine is contraindicated in young people 20-35 years old, suffering from chronic myeloid leukemia. The patient develops profuse bleeding, the drug is not very effective to stop it.
The drug is not included in the list of agents intended for symptomatic therapy and antifibrinolytic drugs indicated for promyelocytic leukemia. Etamsilat injections are not effective in the case of minor bleeding, they should not be administered alone.
Mode of application
The drug is injected intramuscularly. During surgery, your doctor will prescribe an IV medication. For the treatment of acute erosive gastritis, complicated by bleeding, Etamzilate can be injected, which stimulates the formation of blood corpuscles.
The drug is administered at 2 ml / m or / in / in to eliminate hemorrhoidal bleeding, it is used as part of complex therapy.
In the case of profuse blood loss in gynecology, in order to ensure stable hemostasis, the medication is administered intravenously as part of complex therapy, combined with transfusion of blood components, and the use of antifibrinolytics. For the treatment of Randu-Osler disease, the drug is injected at 20 mg / kg 3-4 times a day.
Dosing regimen and overdose
Medication is administered to adults in an amount of 0.25-0.25 g, for emergency care, its amount is increased to 357 g. 60 minutes before the start of the operation, 0.25-0.5 g is injected intravenously.
Children during surgery are injected intravenously with 8-10 mg / kg or are given medication in tablets for prophylaxis. Bleeding in diabetic angiopathy is eliminated by administering a medication in an amount of 0.25-0.5 g / m 3 times a day. The course of therapy lasts 3 months.
The dose of the drug is calculated by the doctor depending on the weight and age of the patient.
In case of an overdose of a medication, the patient's general condition worsens, it is necessary to apply special antidotes. A patient with glucose or galactose malabsorption syndrome may develop severe pathology.
Side effects
A hemostatic injection, even after a single use, can cause:
- headache;
- dizziness;
- violation of sensitivity in the lower extremities.
Often, a patient has red spots on the skin of the face, which are a sign of a dermatological inflammatory process.
Frequent phenomena after using the drug are considered to be:
- nausea;
- heartburn;
- pain in the epigastric region.
Drip injection of the drug may be accompanied by: a decrease in the systolic blood pressure.
Possible adverse reactions after i / m or i / v administration of the medication. The patient develops an allergic reaction, the number of B-lymphocytes decreases.
The doctor does not use medication as the only means of eliminating bleeding, since the drug has a short-term effect. The drug with a jet injection at a dose of 1 g lowers blood pressure within 10 minutes.
special instructions
As a hemostatic agent, a medication is used when there is a risk of bleeding. If the drug is used as an angioprotector, it is prescribed until the risk of microcirculation disturbance is completely eliminated (for up to 2 months).
Sometimes the contents of the ampoule are used for local treatment (after tooth extraction). Sterile cotton wool is impregnated with a solution and applied to the wound; the medicine is not suitable for use if the composition is yellow.
In hemophilia, the drug helps the patient to increase blood clotting, affects the number of platelets. It is necessary to drink the medicine only as directed by a doctor, sometimes after an injection, blood pressure can drop to 60 mm Hg. Art., the patient has dizziness.
Application during pregnancy and lactation
The use of the drug in the expectant mother is necessary if the drug has a positive effect. During pregnancy, it increases blood clotting with an incipient miscarriage. In the first trimester, it is administered concurrently with progesterone.
In the hospital, the doctor uses medication injections if symptoms of incomplete placenta previa appear, a hematoma has developed, and there is a threat of miscarriage.
When breastfeeding, the medication is prescribed by a hematologist. It is necessary to conduct a blood test, since the drug can cause strong platelet aggregation, and the patient develops symptoms of ischemic stroke.
Drug interactions
The medication should not be combined in one syringe with many drugs.
It is allowed to combine a hemostatic agent with drugs such as:
- Aminocaproic acid;
- Menadione sodium bisulfite.
In closed abdominal trauma, Ciprofloxacin infusion solution is incompatible with Etamsylate. They must be entered separately.
Furosemide solution, intended for intramuscular and intravenous administration, is not allowed to be mixed in the same syringe with a hemostatic drug.
Particular attention must be paid when providing emergency surgical care for abdominal trauma (closed). Etamsilate is urgently injected in the amount of 1-2 ampoules intravenously, and then Tranexam is used. The angioprotector interacts with drugs such as:
- Allopurinol;
- Aspirin;
- Atarax;
- Ibuprofen;
- Concor;
- Mexidol;
- Midocalm;
- Phenazepam.
The drug does not react with medications used for the treatment of emergency conditions:
- Tramadol;
- Prednisolone;
- Pentoxifylline.
Terms of sale and storage
The hemostatic is a prescription drug. The drug is stored for 3 years, it is not recommended to use it after the expiration date indicated on the package.
Instructions for the medical use of the medicinal product
ETAMZILATE
Tradename
Etamsilat
International non-proprietary name
Etamsilat
Dosage form
Solution for injection 12.5%
Composition
1 ml of solution contains
active substance - etamsylate 125 mg,
excipients: sodium metabisulfite, sodium sulfite anhydrous, disodium edetate (Trilon B), water for injection.
Description
Transparent, colorless or slightly creamy liquid
Pharmacotherapeutic group
Hemostatics. Vitamin K and other hemostatics. Other systemic hemostatics. Etamsilat.
ATX code B02B X01.
Pharmacological properties
Pharmacokinetics
After intravenous (i / v) or intramuscular (i / m) administration of etamsylate at a dose of 500 mg, its concentration in blood plasma after 1 hour is 30 μg / ml. The hemostatic effect with intravenous administration of Etamsylate occurs in 5-15 minutes, the maximum effect is in 1-2 hours, the action lasts 4-6 hours. With i / m administration, the hemostatic effect occurs in 30-60 minutes. The half-life after intravenous administration is 1.9 hours, after intravenous administration - 2.1 hours. 95% of the administered drug binds to plasma proteins. Etamsylate is not metabolized and is excreted unchanged from the body mainly in the urine (\u003e 80%), partially excreted in the bile and feces.
Pharmacodynamics
The drug has a hemostatic effect. The hemostatic effect is due to an increase in the interaction between the endothelium and platelets, which promotes platelet adhesion and aggregation, and, ultimately, leads to stopping or reducing bleeding. Etamsylate stimulates the formation of platelets and their release from the bone marrow, accelerates the formation of tissue thromboplastin, increases the rate of formation of a primary thrombus at the site of injury and enhances its retraction. Etamsylate enhances the formation of mucopolysaccharides with a high molecular weight in the capillary wall, increases capillary resistance, normalizes their permeability in pathological processes and improves microcirculation. Against the background of treatment with Etamsilat, pathologically altered hemostasis parameters are restored.
Indications for use
Prevention and control of bleeding during surgery:
In otorhinolaryngology (tonsillectomy, microsurgery on the ear)
Ophthalmology (keratoplasty, cataract removal, antiglaucoma
operations)
In dentistry (removal of cysts, granulomas, tooth extraction)
In urology (prostatectomy)
In surgery (operations on well-vascularized organs and tissues)
In gynecology
In traumatology
In emergency cases with pulmonary, intestinal bleeding
Metro- and menorrhagia with fibromas
Diabetic angiopathies
Hemorrhagic diathesis (including in emergency cases)
Method of administration and dosage
Etamsylate is used intravenously, intramuscularly, subconjunctivally or retrobulbar. For prophylactic purposes, the drug is administered intravenously or intramuscularly to adults 1 hour before surgery, 0.25-0.5 g (2-4 ml of a 12.5% \u200b\u200bsolution). If necessary, during the operation, it is administered intravenously in a dose of 2-4 ml of a 12.5% \u200b\u200bsolution. If there is a danger of postoperative bleeding, 4-6 ml of a 12.5% \u200b\u200bsolution per day is administered for prophylactic purposes. For medicinal purposes, in emergency cases, Etamsilat is administered to adults intravenously or intramuscularly (2-4 ml of a 12.5% \u200b\u200bsolution), and then 2 ml every 4-6 hours. In the treatment of metrorrhagia and menorrhagia, Etamsylate is prescribed 0.25 g (2 ml of 12.5% \u200b\u200bsolution) parenterally every 6-8 hours for 5-10 days, and then 0.25 g (2 ml 12.5 % solution) parenterally 2 times a day during bleeding and 2 subsequent cycles.
For diabetic angiopathies, Etamsilat is prescribed intramuscularly (10-14 days), 2 ml 2 times a day.
Subconjunctival or retrobulbar (keratoplasty, cataract removal, glaucoma surgery, etc.), 1 ml of a 12.5% \u200b\u200bsolution is injected.
For children, including newborns, with severe hemorrhages, the drug is administered once intravenously or intramuscularly, 0.5-2 ml, taking into account body weight (10-15 mg / kg).
You can apply the injection solution topically: a sterile swab soaked in the drug is applied to the wound.
The maximum single dose for adults is 4 mg (0.5 g), the daily dose is 14 mg (1.75 g).
Side effects
Headache, dizziness
Decreased blood pressure, a feeling of heaviness in the region of the heart
Facial hyperemia, paresthesia of the lower extremities
Allergic rash
Allergic reactions (skin rashes, anaphylactic shock, life-threatening asthma attacks)
Backache
Nausea, bitterness in the mouth, epigastric pain, diarrhea
Contraindications
Hypersensitivity to the drug
Hemorrhages due to anticoagulant drugs
History of thrombosis or embolism
Lactation period
Bronchial asthma
Hemoblastosis in children (lymphatic and myeloid leukemia, osteosarcoma)
Acute porphyria
Drug interactions
Etamsilat solution should not be mixed in the same syringe with other drugs. When used together with rheopolyglucin, the effects of both drugs are completely inhibited. If necessary, intravenous drip of the drug, Etamsilat is added to a glucose solution or physiological sodium chloride solution.
special instructions
Caution is required in patients with a history of thrombosis or thromboembolism. For hemorrhagic complications associated with an overdose of anticoagulants, it is necessary to use specific antidotes. Etamsylate is prescribed only as an adjunct and, mainly, for violations of the platelet-vascular component of hemostasis. The drug is not effective in patients with thrombocytopenia.
It is prescribed with caution to patients with cardiac arrhythmias and angina pectoris.
Etamsylate contains sulfites, which is why it is also necessary to be careful when administering it to patients with bronchial asthma and allergies.
In case of allergic reactions, treatment should be stopped immediately.
Pregnancy
The use of Etamsilat during pregnancy is possible only if the expected effect of therapy outweighs the potential risk to the fetus.
Features of the effect of the drug on the ability to drive a vehicle or potentially dangerous mechanisms
During therapy, one should be careful to engage in hazardous activities requiring speed of motor and mental reactions (including driving a car), since the drug can cause transient dizziness or a decrease in blood pressure.
Overdose
There is no data on drug overdose. Side effects are transient and do not require special measures.
Release form and packaging
2 ml of the drug is poured into glass ampoules.
10 ampoules, together with instructions for medical use in the state and Russian languages \u200b\u200band a scarifier or a cutting ceramic disc, are placed in a cardboard box.
